Home Health Costs Topics

Health Costs

The MIDTERMS

“...the search for a single top issue through polling questions — whether it’s health costs, or gas prices, or the cost of food — is artificial. People worry about and experience these costs together. There is no top issue, unless that issue is the catchall, ‘cost of living.’” — Drew Altman, KFF Founding President and CEO

Are Health Care Costs THE Top Issue for Voters?

In a new column, Dr. Drew Altman, Founding President and CEO, analyzes the polling on health costs as a voting issue and concludes that there is no one top voting issue. He writes: “I have come to the conclusion that the search for a single top issue through polling questions—whether it’s health costs, or gas prices, or the cost of food—is artificial. People worry about and experience these costs together. There is no top issue, unless that issue is the catchall, “cost of living.”

Health System Tracker

New and noteworthy

How Unaffordable is Health Care and What Can We Do About It?

Event Date:

On Tuesday, July 21, three experts joined Health Wonk Shop series moderator Larry Levitt in an hour-long discussion of health care affordability. During the discussion, panelists considered affordability from a variety of perspectives, including how to define affordability and the question of affordability for whom, how to measure it, and what can be done to address affordability and the underlying cost of health care.

Latest News

More KFF Health News

Stay informed.

Get KFF's latest on Health Costs

Stay informed.

Get KFF's latest on Health Costs

View the Latest: Health Costs

Filter

List Grid

951 - 960 of 1,603 Results

  • Surprise Bills Often Hit in Emergencies

    From Drew Altman

    In an Axios column, Drew Altman previews new data highlighting that people with critical health issues are especially vulnerable to these bills. 

  • Ongoing Challenges with Hospital Price Transparency

    Issue Brief

    This analysis examines transparency data currently shared by hospitals to comply with federal law and finds that they are messy, inconsistent and confusing, making it challenging if not impossible for patients or researchers to use them to compare prices. Many of these shortcomings stem from a lack of specificity in the requirements for what hospitals must report.

  • Analysis: Inconsistencies Within Hospital Price Transparency Data Make Cost Comparisons Difficult

    News Release

    Since 2021, federal law has required hospitals to publicly post information about their standard prices and negotiated discount rates for common health services to encourage consumers to compare prices and to promote competition. To date, however, the transparency data currently shared by hospitals to comply with the law are messy, inconsistent and confusing, making it challenging, if not impossible, for patients or researchers to use them to compare prices across hospitals or payers, a new…

  • Nonprofit Hospitals’ Tax-Exempt Status Worth About $28 Billion, New KFF Analysis Finds

    News Release

    Editor's Note: The press release was updated on March 27, 2023, to reflect corrections in the underlying analysis, resulting in a modest increase in the total estimated value of tax exemption, from $27.6 to $28.1 billion. The tax-exempt status of the nation’s nonprofit hospitals collectively was worth about $28 billion in 2020, a new KFF analysis of hospital financial data estimates. The total reflects the estimated federal, state and local taxes that nonprofit hospitals do…

  • How Have Costs Associated With Obesity Changed Over Time?

    Issue Brief

    This analysis finds that, among people with large employer health plans, those with an obesity diagnosis on average have higher total and out-of-pocket spending than those without an obesity diagnosis. It also examines the cost of common surgical and pharmacological treatments for obesity. 

  • Poll: Nearly Half of Adults Would Be Interested in Prescription Weight-Loss Drugs, But Enthusiasm Fades Based on Lack of Coverage and Risk of Regaining Weight 

    News Release

    Nearly half (45%) of the public are at least somewhat interested in taking a prescription weight-loss drug, including many who say they only want to lose a little weight, though many people lose interest when presented with potential financial and medical drawbacks, the latest KFF Health Tracking Poll reveals.The poll gauges the public’s interest in using prescription drugs to lose weight as a relatively new class of drugs, initially approved to treat diabetes, is garnering…

  • How Do Prices of Drugs for Weight Loss in the U.S. Compare to Peer Nations’ Prices?

    Issue Brief

    A class of drugs initially approved for diabetes treatment has captured the public’s and policymakers’ attention as interest in their off-label use for weight loss rises. The weight-loss benefits of these drugs have led to their prescribed use for obesity or overweight treatment. A new analysis compares list prices for semaglutide—including Ozempic, which has been approved in the U.S. for diabetes, and Wegovy, which has the same active ingredient and has been approved for weight…